Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: P&G v. Cumberland-Swan

This article was originally published in The Tan Sheet

Executive Summary

P&G v. Cumberland-Swan: Cumberland-Swan will pay $85,000 to P&G as part of the settlement of a trade dress infringement suit filed in July ("The Tan Sheet" Sept. 19, p. 5), P&G announces Dec. 21. The suit charged Cumberland-Swan with selling products in packages that infringed P&G's Head & Shoulders shampoo, Secret and Sure antiperspirants and deodorants and Noxzema skin creams. "Soon after" the suit was filed, the products were removed from F&M's store shelves, P&G said, and Cumberland-Swan must change the products' labeling under a consent judgment. The suits against F&M and Evron Industries, making similar charges, are ongoing...

You may also be interested in...



Gillette Drives P&G Health Care Sales Growth, Boosts Beauty Segment

The addition of Gillette Oral Care to Procter & Gamble's portfolio has driven P&G Health Care sales up 21% to $2.4 bil. for the third quarter ended March 31, the firm reported during a May 3 analyst call

Gillette Drives P&G Health Care Sales Growth, Boosts Beauty Segment

The addition of Gillette Oral Care to Procter & Gamble's portfolio has driven P&G Health Care sales up 21% to $2.4 bil. for the third quarter ended March 31, the firm reported during a May 3 analyst call

Gillette Drives P&G Health Care Sales Growth, Boosts Beauty Segment

The addition of Gillette Oral Care to Procter & Gamble's portfolio has driven P&G Health Care sales up 21% to $2.4 bil. for the third quarter ended March 31, the firm reported during a May 3 analyst call

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS083589

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel